Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility HELP
Based on 20,002 articles published since 2008
||||

These are the 20002 published articles about Infertility that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
76 Guideline Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. 2011

Morice, Philippe / Denschlag, Dominik / Rodolakis, Alex / Reed, Nick / Schneider, Achim / Kesic, Vesna / Colombo, Nicoletta / Anonymous2750698. ·ESGO Task Force for Fertility Preservation in Gynecological Cancer, Geneva, Switzerland. morice@igr.fr ·Int J Gynecol Cancer · Pubmed #21697684.

ABSTRACT: In young patients with borderline ovarian tumor a conservative treatment approach does not seem to have a significant impact on survival, and the outcome regarding fertility is good in general. It can be considered even if noninvasive peritoneal implants are discovered at the time of the initial surgery. In contrast, in patients with epithelial ovarian cancer, conservative surgery should be considered only in adequately staged patients, with a stage IA grade 1 (and probably 2) serous, mucinous or an endometrioid tumor, including a careful follow-up. Such an approach could also probably be discussed in stage IC grade 1 disease.In patients with nonepithelial malignant ovarian tumors, conservative surgery is also feasible, particularly in patients with malignant germ cell tumors because of their high chemosensitivity leading to an excellent prognosis in general.

77 Guideline ESHRE's good practice guide for cross-border reproductive care for centers and practitioners. 2011

Shenfield, F / Pennings, G / De Mouzon, J / Ferraretti, A P / Goossens, V / Anonymous3580692. ·University College London Hospitals Trust, Reproductive Medicine Unit, London, UK. ·Hum Reprod · Pubmed #21505043.

ABSTRACT: This paper outlines ESHRE's guidance for centers and physicians providing fertility treatment to foreign patients. This guide aims to ensure high-quality and safe assisted reproduction treatment, taking into account the patients, their future child and the interests of third-party collaborators such as gametes donors and surrogates. This is achieved by including considerations of equity, safety, efficiency, effectiveness (including evidence-based care), timeliness and patient centeredness.

78 Guideline [Semen analysis: spermiogram according to WHO 2010 criteria]. 2011

Gottardo, F / Kliesch, S / Anonymous5110681. ·Centrum für Reproduktionsmedizin und Andrologie, WHO Kollaborationszentrum zur Erforschung der männlichen Fertilität, Ausbildungszentrum European Academy of Andrology (EAA), Universitätsklinikum Münster, Domagkstr. 11, 48149 Münster, Deutschland. ·Urologe A · Pubmed #21161160.

ABSTRACT: Semen analysis plays a key role in the diagnostics of male infertility. Semen analysis has to be performed according to World Health Organisation (WHO) criteria. The updated version of the WHO manual was completed at the end of 2009 and published in 2010. Standard procedures in semen analysis include evaluation of sperm concentration, motility, morphology and vitality. In this new version particular attention has been paid to internal and external quality control, helping to identify and correct incidental and systematic errors both in routine analysis as well as in the field of research. The new manual describes all laboratory solutions, procedures and calculation formulas, and focuses on the definition of cryptozoospermia or azoospermia. A chapter concerning cryopreservation of spermatozoa has been newly integrated. The following overview presents the most important aspects of the updated WHO manual.

79 Guideline Endometriosis: diagnosis and management. 2010

Leyland, Nicholas / Casper, Robert / Laberge, Philippe / Singh, Sukhbir S / Anonymous4390693. · ·J Obstet Gynaecol Can · Pubmed #21545757.

ABSTRACT: OBJECTIVE: To improve the understanding of endometriosis and to provide evidence-based guidelines for the diagnosis and management of endometriosis. OUTCOMES: OUTCOMES evaluated include the impact of the medical and surgical management of endometriosis on women's experience of morbidity and infertility. METHODS: Members of the guideline committee were selected on the basis of individual expertise to represent a range of practical and academic experience in terms of both location in Canada and type of practice, as well as subspecialty expertise along with general gynaecology background. The committee reviewed all available evidence in the English and French medical literature and available data from a survey of Canadian women. Recommendations were established as consensus statements. The final document was reviewed and approved by the Executive and Council of the SOGC. RESULTS: This document provides a summary of up-to-date evidence regarding diagnosis, investigations, and medical and surgical management of endometriosis. The resulting recommendations may be adapted by individual health care workers when serving women with this condition. CONCLUSIONS: Endometriosis is a common and sometimes debilitating condition for women of reproductive age. A multidisciplinary approach involving a combination of lifestyle modifications, medications, and allied health services should be used to limit the impact of this condition on activities of daily living and fertility. In some circumstances surgery is required to confirm the diagnosis and provide therapy to achieve the desired goal of pain relief or improved fecundity. Women who find an acceptable management strategy for this condition may have an improved quality of life or attain their goal of successful pregnancy. EVIDENCE: Medline and Cochrane databases were searched for articles in English and French on subjects related to endometriosis, pelvic pain, and infertility from January 1999 to October 2009 in order to prepare a Canadian consensus guideline on the management of endometriosis. VALUES: The quality of evidence was rated with use of the criteria described by the Canadian Task Force on Preventive Health Care. Recommendations for practice were ranked according to the method described by the Task Force. See Table 1. BENEFITS, HARMS, AND COSTS: Implementation of the guideline recommendations will improve the care of women with pain and infertility associated with endometriosis.

80 Guideline [Management of the infertile couple]. 2010

Anonymous4610683. · ·J Gynecol Obstet Biol Reprod (Paris) · Pubmed #21229669.

ABSTRACT: -- No abstract --

81 Guideline [Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. II. Special situations and organisation of medical care]. 2010

Dijkstra, Gerard / Derijks, Luc J J / Houwert, Govert J / Wolf, Hans / van Bodegraven, Ad A / Anonymous8060677. ·Universitair Medisch Centrum Groningen, afd. Maag-Darm-Leverziekten, the Netherlands. ·Ned Tijdschr Geneeskd · Pubmed #21029497.

ABSTRACT: The Dutch national practice guideline 'Diagnosis and treatment of inflammatory bowel diseases (IBD) in adults' describes the multidisciplinary approach for adult patients with (suspected) IBD, recommended following analysis of the literature according to the principles of evidence based guideline development. Ulcerative colitis and Crohn's disease are associated with temporary or permanent extra-intestinal disorders: reactive inflammatory conditions, associated conditions, and those arising as a consequence of long standing, inflammatory, intestinal disease. Treatment is aimed first at the IBD disease process and subsequently at the specific extra-intestinal conditions if complaints persist. The fertility of women with IBD who have not been operated is comparable with those without this complaint. With the exception of methotrexate in both sexes and of sulfasalazine in men, none of the usual medicines for IBD is known to adversely influence fertility. Fertility decreases following abdominal surgery. IBD patients are advised to restrict onset of pregnancy to a longstanding, quiet phase of the disease (ideally > 1 year). The risk of complications during pregnancy is not elevated when IBD is in remission, but is increased during active disease. Nulliparae with an ileoanal pouch have approximately 50% long term risk of developing faecal incontinence; a planned full-term Caesarean section may be beneficial in such cases. Complicated perianal disease is similarly an indication for non-vaginal delivery. The life expectancy for patients with ulcerative colitis is normal, but is slightly lower in patients with Crohn's disease. These positive findings have not yet been incorporated into the practice of life insurance providers. The diversity of IBD patient health care and its delivery by many professionals places stringent requirements on the organisation of care by hospitals and those providing treatment. The transfer process from paediatric specialist to gastroenterologist affects both patients and parents deeply.

82 Guideline Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice. 2010

Akande, Valentine / Turner, Cathy / Horner, Paddy / Horne, Andrew / Pacey, Allan / Anonymous4940672. ·Bristol Centre for Reproductive Medicine, Southmead Hospital, Bristol, UK. valentine.akande@bristol.ac.uk ·Hum Fertil (Camb) · Pubmed #20849196.

ABSTRACT: Chlamydia trachomatis infection of the genital tract is the most common sexually transmitted infection and has a world-wide distribution. The consequences of infection have an adverse effect on the reproductive health of women and are a common cause of infertility. Recent evidence also suggests an adverse effect on male reproduction. There is a need to standardise the approach in managing the impact of C. trachomatis infection on reproductive health. We have surveyed current UK practice towards screening and management of Chlamydia infections in the fertility setting. We found that at least 90% of clinicians surveyed offered screening. The literature on this topic was examined and revealed a paucity of solid evidence for estimating the risks of long-term reproductive sequelae following lower genital tract infection with C. trachomatis. The mechanism for the damage that occurs after Chlamydial infections is uncertain. However, instrumentation of the uterus in women with C. trachomatis infection is associated with a high risk of pelvic inflammatory disease, which can be prevented by appropriate antibiotic treatment and may prevent infected women from being at increased risk of the adverse sequelae, such as ectopic pregnancy and tubal factor infertility. Recommendations for practice have been proposed and the need for further studies is identified.

83 Guideline Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. 2010

Vause, Tannys D R / Cheung, Anthony P / Sierra, Sony / Claman, Paul / Graham, James / Guillemin, Jo-Anne / Lapensée, Louise / Steward, Sabrina / Wong, Benjamin Chee-Man / Anonymous4490672. · ·Int J Gynaecol Obstet · Pubmed #20848729.

ABSTRACT: OBJECTIVE: To review current non-pharmacologic and pharmacologic options for ovulation induction in women with polycystic ovary syndrome (PCOS). OPTIONS: This guideline reviews the evidence for the various options for ovulation induction in PCOS. OUTCOMES: Ovulation, pregnancy and live birth rates, risks, and side effects are the outcomes of interest. EVIDENCE: Published literature was retrieved through searches of Medline using appropriate controlled vocabulary and key words. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Grey (unpublished) literature was identified through searching the websites of health technology assessment and of health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. VALUES: The evidence gathered was reviewed and evaluated by the Reproductive Endocrinology and Infertility Committee of the Society of Obstetricians and Gynaecologists of Canada. The quality of evidence was quantified using the Canadian Task Force on Preventive Health Care. BENEFITS, HARMS, AND COSTS: Benefits include weight reduction and improvements in ovulation, pregnancy, and live birth rates. Potential harms include medication side effects and multiple pregnancies. VALIDATION: These guidelines have been reviewed and approved by the Reproductive Endocrinology and Infertility Committee of the SOGC.

84 Guideline Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010

Pentheroudakis, G / Orecchia, R / Hoekstra, H J / Pavlidis, N / Anonymous3260663. ·Department of Medical Oncology, Ioannina University Hospital, Greece. ·Ann Oncol · Pubmed #20555095.

ABSTRACT: -- No abstract --

85 Guideline [Ovulation induction in polycystic ovary syndrome]. 2010

Vause, Tannys D R / Cheung, Anthony P / Anonymous6500661 / Anonymous6510661. ·Ottawa (Ont.). · Vancouver (C.-B.). ·J Obstet Gynaecol Can · Pubmed #20500960.

ABSTRACT: -- No abstract --

86 Guideline Ovulation induction in polycystic ovary syndrome. 2010

Vause, Tannys D R / Cheung, Anthony P / Anonymous6490661. ·Ottawa ON. · Vancouver BC. ·J Obstet Gynaecol Can · Pubmed #20500959.

ABSTRACT: OBJECTIVE: To review current non-pharmacologic and pharmacologic options for ovulation induction in women with polycystic ovary syndrome (PCOS). OPTIONS: This guideline reviews the evidence for the various options for ovulation induction in PCOS. OUTCOMES: Ovulation, pregnancy and live birth rates, risks, and side effects are the outcomes of interest. EVIDENCE: Published literature was retrieved through searches of Medline using appropriate controlled vocabulary and key words. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Grey (unpublished) literature was identified through searching the websites of health technology assessment and of health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. VALUES: The evidence gathered was reviewed and evaluated by the Reproductive Endocrinology and Infertility Committee of the Society of Obstetricians and Gynaecologists of Canada. The quality of evidence was quantified using the Canadian Task Force on Preventive Health Care. BENEFITS, HARMS, AND COSTS: Benefits include weight reduction and improvements in ovulation, pregnancy, and live birth rates. Potential harms include medication side effects and multiple pregnancies. VALIDATION: These guidelines have been reviewed and approved by the Reproductive Endocrinology and Infertility Committee of the SOGC. SPONSOR: The Society of Obstetricians and Gynaecologists of Canada. RECOMMENDATIONS 1. Weight loss, exercise, and lifestyle modifications have been proven effective in restoring ovulatory cycles and achieving pregnancy in overweight women with PCOS and should be the first-line option for these women. (II-3A) Morbidly obese women should seek expert advice about pregnancy risk. (III-A) 2. Clomiphene citrate has been proven effective in ovulation induction for women with PCOS and should be considered the first-line therapy. Patients should be informed that there is an increased risk of multiple pregnancy with ovulation induction using clomiphene citrate. (I-A) 3. Metformin combined with clomiphene citrate may increase ovulation rates and pregnancy rates but does not significantly improve the live birth rate over that of clomiphene citrate alone.(I-A) Metformin may be added to clomiphene citrate in women with clomiphene resistance who are older and who have visceral obesity. (I-A) 4. Gonadotropin should be considered second-line therapy for fertility in anovulatory women with PCOS. The treatment requires ultrasound and laboratory monitoring. High costs and the risk of multiple pregnancy and ovarian hyperstimulation syndrome are drawbacks of the treatment. (II-2A) 5. Laparoscopic ovarian drilling may be considered in women with clomiphene-resistant PCOS, particularly when there are other indications for laparoscopy. (I-A) Surgical risks need to be considered in these patients. (III-A) 6. In vitro fertilization should be reserved for women with PCOS who fail gonadotropin therapy or who have other indications for IVF treatment. (II-2A).

87 Guideline Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. 2010

Lyus, Richard / Lohr, Patricia / Prager, Sarah / Anonymous3220658. · ·Contraception · Pubmed #20399942.

ABSTRACT: Two intrauterine devices (IUDs) are available in the United States, the levonorgestrel-bearing intrauterine system (Mirena) and the copper-bearing T380A (Paragard). These devices have very low typical-use failure rates but are used by only a minority of women. In particular, there is concern about their use in nulliparous women. We review the available data to address common concerns about using IUDs in this population and show that nulliparous women desiring effective contraception should be considered candidates for IUDs.

88 Guideline Uterine transplantation FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. 2009

Milliez, Jacques. ·FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. figo@figo.org ·Int J Gynaecol Obstet · Pubmed #19501356.

ABSTRACT: -- No abstract --

89 Guideline Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. 2009

Dequeker, Els / Stuhrmann, Manfred / Morris, Michael A / Casals, Teresa / Castellani, Carlo / Claustres, Mireille / Cuppens, Harry / des Georges, Marie / Ferec, Claude / Macek, Milan / Pignatti, Pier-Franco / Scheffer, Hans / Schwartz, Marianne / Witt, Michal / Schwarz, Martin / Girodon, Emmanuelle. ·Center for Human Genetics, Campus Gasthuisberg, KULeuven, Belgium. ·Eur J Hum Genet · Pubmed #18685558.

ABSTRACT: The increasing number of laboratories offering molecular genetic analysis of the CFTR gene and the growing use of commercial kits strengthen the need for an update of previous best practice guidelines (published in 2000). The importance of organizing regional or national laboratory networks, to provide both primary and comprehensive CFTR mutation screening, is stressed. Current guidelines focus on strategies for dealing with increasingly complex situations of CFTR testing. Diagnostic flow charts now include testing in CFTR-related disorders and in fetal bowel anomalies. Emphasis is also placed on the need to consider ethnic or geographic origins of patients and individuals, on basic principles of risk calculation and on the importance of providing accurate laboratory reports. Finally, classification of CFTR mutations is reviewed, with regard to their relevance to pathogenicity and to genetic counselling.

90 Guideline [National guideline 'Cryopreservation of ovarian tissue']. 2008

Heineman, M J / Beerendonk, C C M / Kaandorp, C J E. ·Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Verloskunde en Gynaecologie, Amsterdam. m.j.heineman@amc.uva.nl ·Ned Tijdschr Geneeskd · Pubmed #19051796.

ABSTRACT: The treatment of children and young adults with cancer increasingly results in cure, but for a number of female patients this is at the expense of infertility. For women and girls with cancer and the wish to have children in the future, cryopreservation of ovarian tissue may be a solution in the absence of alternatives for the conservation of fertility. Because of the uncertain effectiveness and safety of cryopreservation of ovarian tissue, the Dutch national guideline 'Cryopreservation of ovarian tissue' advises removing and freezing ovarian tissue only if this is done within the framework of scientific research. Reimbursement of this procedure and financing of the relevant and necessary research have not yet been arranged.

91 Guideline Ovarian tissue and oocyte cryopreservation. 2008

Anonymous4220615 / Anonymous4230615. · ·Fertil Steril · Pubmed #19007638.

ABSTRACT: Although currently investigational, ovarian tissue cryopreservation and oocyte cryopreservation hold promise for future female fertility preservation, particularly following aggressive chemotherapy and/or radiotherapy treatment protocols.

92 Guideline Guidelines for reducing the risk of viral transmission during fertility treatment. 2008

Anonymous3940615. · ·Fertil Steril · Pubmed #19007616.

ABSTRACT: These guidelines provide strategies, based on scientific principles and clinical experience, for reducing the risk of virus transmission in couples seeking treatment for infertility.

93 Guideline Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. 2008

Anonymous6030596. · ·Fertil Steril · Pubmed #18406835.

ABSTRACT: Exogenous P supplementation is a common element of treatment regimens for infertility, particularly those relating to the assisted reproductive technologies.

94 Guideline [Optimal evaluation of the infertile male. 2007 French urological association guidelines]. 2008

Huyghe, E / Izard, V / Rigot, J-M / Pariente, J-L / Tostain, J / Anonymous3420596. ·Service d'urologie-andrologie, hôpital Rangueil, CHU de Toulouse, 1, avenue du Pr Jean-Poulhès, 31059 Toulouse cedex 9, France. huyghe.e@chu-toulouse.fr ·Prog Urol · Pubmed #18396236.

ABSTRACT: An infertility evaluation should be performed if a couple has not achieved conception after one year of unprotected intercourse. An evaluation should be performed earlier if male or female infertility risk factors exist and if the couple questions its fertility potential. The initial screening of the male should include a reproductive history and a physical examination performed by a urologist or a specialist in male fertility and two semen analyses. Additional procedures and testing may be used to elucidate problems discovered during the full evaluation. The minimal initial endocrine evaluation should include serum total testosterone and serum follicle-stimulating hormone levels. An endocrine evaluation should be performed if sperm concentration is abnormally low, sexual function is impaired, and when other clinical findings suggest a specific endocrinopathy. A postejaculatory urinalysis should be performed if ejaculate volume is less than 1 mL, except in patients with bilateral vasal agenesis or possible hypogonadism. With a diagnosis of retrograde ejaculation, specific management should be considered before advising assisted reproductive technology. Scrotal ultrasonography is indicated when physical examination of the scrotum is difficult or inadequate, or when a testicular mass is suspected. Transrectal ultrasonography (TRUS) is indicated in patients who are azoospermic or have a low ejaculate volume. Specialized testing of semen is not required for routine diagnosis of male infertility. However, some tests may be useful for a few patients to identify a male factor contributing to unexplained infertility, or to select therapy (e.g., assisted reproductive technology). Before performing intracytoplasmic sperm injection, karyotyping and Y-chromosome analysis should be offered to men who have nonobstructive azoospermia and severe oligospermia. Genetic testing for gene mutations of the ABCC7 (ex-CFTR) gene should be offered to male and female partners before proceeding with treatments that use the sperm of men with congenital bilateral absence of the vasa deferentia or congenital unilateral abnormality of the seminal tract. Genetic counseling may be offered when a genetic abnormality is suspected in the male or female partner, and it should be provided when a genetic abnormality is detected. Genetic testing in the female partner, when non symptomatic, should only be advised by a physician from a multidisciplinary team registered by the ministry of health. Evaluation by testis biopsy and deferentography should be performed by a urologist or an andrologist registered for sperm retrieval.

95 Guideline Diagnostic laparoscopy guidelines : This guideline was prepared by the SAGES Guidelines Committee and reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), November 2007. 2008

Hori, Yumi / Anonymous2120596. ·Society of American Gastrointestinal and Endoscopic Surgeons, 11300 West Olympic Blvd, Suite 600, Los Angeles, CA 90064, USA. sagesweb@sages.org ·Surg Endosc · Pubmed #18389320.

ABSTRACT: -- No abstract --

96 Guideline Consensus on infertility treatment related to polycystic ovary syndrome. 2008

Anonymous5930591. · ·Fertil Steril · Pubmed #18243179.

ABSTRACT: The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. On the basis of the currently available evidence, a group of experts reached a consensus regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counseling should be provided emphasizing the importance of lifestyle, especially weight reduction and exercise in overweight women, smoking, and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotropins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotropins is associated with increased chances for multiple pregnancy, and, therefore, intense monitoring of ovarian response is required. Laparoscopic ovarian surgery alone is usually effective in less than 50% of women, and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC-gonadotropin paradigm) is reported to be highly effective with a cumulative singleton live-birth rate of 72%. Recommended third-line treatment is in vitro fertilization (IVF). More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-line, second-line, or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.

97 Editorial Empiric Medical and Nutritional Therapy for Idiopathic Male Infertility: How Good Is the Evidence for What Works and Does Not? 2019

Clark, Joseph Y. ·Division of Urology, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: jclark13@pennstatehealth.psu.edu. ·Eur Urol · Pubmed #30711332.

ABSTRACT: -- No abstract --

98 Editorial Hot topics in female infertility: an afterword. 2019

Humaidan, Peter / Esteves, Sandro C / Roque, Matheus / Agarwal, Ashok. ·Faculty of Health, Aarhus University, Aarhus, Denmark - peter.humaidan@midt.rm.dk. · Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark - peter.humaidan@midt.rm.dk. · Faculty of Health, Aarhus University, Aarhus, Denmark. · Andrology and Human Reproduction Clinic, ANDROFERT, Campinas, Brazil. · Division of Urology, Department of Surgery, University of Campinas (UNICAMP), Campinas, Brazil. · Center for Reproductive Medicine, ORIGEN, Rio de Janeiro, Brazil. · American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, USA. ·Panminerva Med · Pubmed #30674182.

ABSTRACT:

99 Editorial Female infertility and assisted reproductive technology. 2019

Esteves, Sandro C / Humaidan, Peter / Roque, Matheus / Agarwal, Ashok. ·Andrology and Human Reproduction Clinic, ANDROFERT, Campinas, Brazil - s.esteves@androfert.com.br. · Division of Urology, Department of Surgery, University of Campinas (UNICAMP), Campinas, Brazil - s.esteves@androfert.com.br. · Faculty of Health, Aarhus University, Aarhus, Denmark - s.esteves@androfert.com.br. · Faculty of Health, Aarhus University, Aarhus, Denmark. · Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark. · ORIGEN - Center for Reproductive Medicine, Rio de Janeiro, Brazil. · American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, USA. ·Panminerva Med · Pubmed #30674179.

ABSTRACT:

100 Editorial Variants in major histocompatibility complex genes: novel factors resulting in male factor infertility? 2019

Lo, Eric M / Pastuszak, Alexander W. ·Baylor College of Medicine, Houston, Texas. · Division of Urology, Department of Surgery, University of Utah, Salt Lake City, Utah. ·Fertil Steril · Pubmed #30611413.

ABSTRACT: -- No abstract --

Back · Next